Objective: Kerala Registry of Epilepsy and Pregnancy had been prospectively evaluating the reproductive issues of women with epilepsy since April 1998. This analysis aimed to estimate the relative risk of major congenital malformations (MCM) to the registrants. Methods: All pregnancies with known outcome in this register until December 2013 were included. Malformation status was evaluated by antenatal ultrasonography, physical examination at birth, echocardiography, and abdomen ultrasonography at 3 months of age and a final review at 1 year of age. Results: There were 1,688 fetuses (singlets 1,643, twins 21, and triplet 1) resulting in 1,622 live births. All were born to women of Asian origin living in South India. The MCM rate for all live births was 6.84% (95% confidence interval [CI] 5. 71-8.18) and for all pregnancy outcomes including fetal loss was 7.11% (95% CI 5.98-8.44). The MCM rates (mean with 95% CI) for exposed group were 6.4% (5.03-8.03) for monotherapy and 9.9% (7.37-13.13) for polytherapy; internal control group (women with epilepsy [WWE] not on antiepileptic drugs [AEDs] in first trimester) 5.6% (3.34-9.11), external control group (women without epilepsy or AED exposure in first trimester) 3.45% (1.94-6.07). Valproate monotherapy group had a dose-dependent relative risk for MCM of 2.6 (95% CI 1.30-5.20) compared to the external control group. The preliminary data on MCM rate for the nine total clobazam monotherapy (22.2%; 95% CI 6.2-54.7) signals increased risk that needs further validation on larger sample size. There was no association between MCM rate and maternal socioeconomic status, epilepsy syndrome, or use of folic acid in first trimester. Significance: This dataset from South India confirms the increased risk of MCM with exposure to AEDs, particularly polytherapy. A dose-dependent increased risk was observed with valproate. The increased risk associated with clobazam monotherapy is an important signal that needs to be confirmed in a larger sample. KEY WORDS: Antiepileptic drug exposure, Teratogenic, Indian women.
The reproductive issues of women with epilepsy (WWE) and the adverse outcomes for their children have gained considerable attention in the recent past. The data from several registries of epilepsy and or antiepileptic drugs (AEDs) and pregnancy have been published recently. [1] [2] [3] There had been wide discussion on what would be an ideal pregnancy registry, how should women be enrolled in prospective pregnancy registries, and the strategies on publishing the data from these registries. 4 Although these registries have several features in common, there are certain differences in their design and methods of ascertaining major congenital malformations (MCMs) that make it difficult to make head-to-head comparisons of their results. 5 Socioeconomic and cultural factors have considerable impact on epilepsy care including pharmacotherapy.
Pregnancy outcome and malformation risk to the fetus are likely to be influenced by geographic and environmental factors, ethnic background, and socioeconomic situations of the subjects. The Kerala Registry of Epilepsy and Pregnancy (KREP) is the only registry that prospectively compiles pregnancy outcome and MCMs for WWE of nonEuropean descent living in low-income circumstances in Asia over a long period. Our objective was to estimate the relative risk of MCMs in children of WWE and identify the factors that influence the same.
Methods
This is a prospective observational single-center registry located in the Kerala State in South India. It is operational since April 1998. General practitioners, gynecologists, and neurologists were referring cases to this registry. All subjects were evaluated by two or more epileptologists, and the diagnosis of epilepsy was confirmed before registration. Detailed history, physical examination, and electroencephalography (EEG) were done on all subjects and magnetic resonance imaging (MRI) or other imaging studies were done on most of them. The registry is following the International League Against Epilepsy (ILAE) classification of seizures (1981) and epilepsy syndrome (1989). 6, 7 All patients with partial seizures (simple or complex partial with our without generalization) are classified as LRE. Generalized seizures with abnormal neurologic examination or structural abnormality on imaging are also classified as LRE. Women who fulfilled criteria for idiopathic generalized epilepsies were classified as generalized epilepsy. Women with generalized seizures without aura or focal onset, normal birth and development, and normal neurologic examination, brain imaging, and EEG examinations were also classified as generalized epilepsy. As per the KREP protocol, 8 women would have six visits to the registry: (1) for preconception care; (2) for pregnancy reporting in the first trimester; (3) for screening of MCM (at 18 weeks of pregnancy) by antenatal ultrasonography (AUS) and estimation of serum alpha fetoprotein; (4) for review of seizure control (at 24-32 weeks); (5) newborn evaluation, echocardiography, and ultrasonography (3 months after delivery); and (6) developmental assessment (at 1 year of age of the baby). This registry is offering a four-stage screening for MCM: (1) antenatal screening by serum alpha fetoprotein estimation and detailed anomaly scan between 12 and 18 weeks of pregnancy; (2) physical examination at birth; (3) physical examination, echocardiography, and abdomen ultrasonography at 3 months of age; and (4) review at 1 year of age for any additional MCM detected after the evaluation at 3 months. A complete malformation screening would require the first three stages. An MCM was defined as a defect detected by imaging or clinical examination in the development of a body part or organ that would significantly impede the quality of life of the child or require a surgical intervention or close monitoring and follow-up. A panel of expert pediatricians, pediatric surgeons, nephrologists, and cardiologists had laid down the criteria for classifying the children for MCM. The same diagnostic criteria were applied throughout the study period from 1998 to 2015. We did not include pregnancies if the MCM status was ascertained by blood tests or ultrasonography before referral to the registry.
There were 2,454 registrations in this registry between 1 April 1998 and 31 Dec 2013. For the purpose of this analysis, we have included registrations only if the pregnancies were completed with known outcome and at least one malformation screening had been prospectively carried out (Table 1) . Erroneous registrations (9) and registrations that remained in the preconception stage (409), pregnancies lost to follow-up before AUS (48) or after AUS (82), continuing pregnancies (94), spontaneous abortions before AUS (89), voluntary abortions before AUS (21), and medical terminations on maternal grounds before AUS (14) were excluded (n = 766). The excluded group was comparable to those who were included with regard to age, region of residence, socioeconomic status and epilepsy classification.
Exposures
Exposure was defined as use of one or more AEDs any time during the first trimester of pregnancy. Women were instructed to record the use of the AEDs, folic acid and seizure count on a daily basis in the pregnancy diary that was given to them. The total daily dose, number of dosages, and the single highest dose for each AED were recorded for each month of pregnancy and postpartum 3 months in the clinical records of the registry. If the dose of a drug was changed during a calendar month, the highest dose used during that month was recorded as the representative dose for the drug. The highest dose of a drug that was used anytime during the
Key points
• Live-born babies with first-trimester exposure to AEDs have higher risk of major congenital malformations (6.84%; 95% CI 5.71-8.18) compared to babies of women without epilepsy and AED exposure (3.45%; 95% CI 1.94-6.07)
• Compared to babies of women without epilepsy and AED exposure, babies exposed to valproate monotherapy had a dose-dependent higher relative risk of malformations (2.6; 95% CI 1.3-5.2)
• Clobazam monotherapy in a small sample showed high malformation rate that needs further confirmation
• MCM rate in this study from India with low middle income and socioeconomic background is comparable to that reported from elsewhere first 3 months of pregnancy (prescribed daily dose [PDD]) was taken as the exposure for that drug. To make comparisons between AEDs and for polytherapy we had also described the dose as a ratio of PDD to daily defined dose (DDD). The DDD as defined by the World Health Organization (WHO) is the assumed average maintenance dose per day for a drug used for its main indication in adults. 9 In the case of polytherapy, the total exposure to multiple AEDs was calculated as the sum of the ratio of PDD/DDD for each of the AEDs used anytime during first trimester of pregnancy. The daily dosage of folic acid is also recorded on a monthly basis. The exposure to other potentially teratogenic drugs, medications, alcohol, tobacco, or radiation during each month of pregnancy is recorded in the clinical record.
Predictors/risk factors
History of malformation or epilepsy on the maternal or paternal side was elicited with a three-generation pedigree chart. The seizure classification, frequency, antecedent illnesses, epilepsy syndrome, EEG, and imaging findings were recorded for each WWE. The past obstetric history of the woman was recorded, with special emphasis on past pregnancies and fetal outcomes.
Socioeconomic status
Socioeconomic status was ascertained by considering the education and occupation of the woman as well as her spouse and their family income. Each of these five variables was assigned scores with a higher score indicating better socioeconomic status. A composite score for socioeconomic status (CSES) was arrived at for each woman by adding the 5 individual scores, with the lowest possible score being 5 and the highest being 50.
Control group
In this analysis, WWE enrolled in the KREP and not using any AEDS anytime during the first trimester were treated as the internal control group. As an external control group we had recruited 319 women without epilepsy in the first trimester of pregnancy and not using AEDs from the antenatal clinic of government hospital. They had socioeconomic background comparable to that of the registrants. Their pregnancy outcome and MCM status were ascertained on the same protocol as our registry.
Statistical analysis
Quantitative data were summarized with mean (standard deviation [SD] ). For data with skewed distributions and for ordinal data, we used median, quartiles, and ranges. Categorical variables were described as percentages. For comparing risk of MCMs between groups, relative risk (RR) was estimated. For inference purpose, 95% confidence intervals (CIs) were calculated for means, percentages, and RRs. For quantitative variables, t-tests were used, and for categorical variables chi-square tests/Fisher's exact tests were used to assess statistical significance. Chi-square tests for trend were used to study trend in MCMs with drug dose. Microsoft Excel, Epi Info Version 3.5.1, and IBM SPSS Statistics version 21 were the used for data organization and statistical analyses.
Results
There were 1,688 fetuses (singlets 1,666, twins 21, and triplet 1) from 1,665 pregnancies included in this analysis. The place of residence was in southern districts of Kerala for 1,508 pregnancies, northern districts of Kerala for 126 cases, and outside Kerala state for 52 pregnancies. The registrations were in the preconception stage for 419 cases (24.8%) and in the first trimester of pregnancy for 1,269 cases (including 383 who had previous pregnancy registered in KREP). The mean age (AE SD) of the WWE at the time of conception was 26.23 AE 4.5 years. The maternal epilepsy syndrome was generalized epilepsy (GE) for 746 women (44.2%) and localization-related epilepsy (LRE) for 942 women (55.8%). The seizure type was generalized for 762 women (45.1%) and partial (focal) with or without generalization for 926 women (54.9%). Their CSES ranged from 10 to 50 (median 23, mean 25.1 AE 9.5). b Voluntary abortion refers to a medical termination of pregnancy wherein the woman requests a termination before 20 weeks of pregnancy (mostly because the woman does not want to proceed with that pregnancy). f Intrauterine death is spontaneous death of the fetus before labor is started and requiring medical intervention to evacuate the products. 
Seizures during pregnancy
Most women (n = 1,192, 70.6%) were seizure free during the first trimester, 496 women (29.4%) had one or more seizures during the first trimester. There were 159 women (9.4%) who had one or more generalized tonic-clonic seizures during this period.
AED exposure
There were 1,021 on monotherapy and 415 on polytherapy with two AEDs (368), three AEDs (39), or four AEDs (8) . The AEDs (n) used were phenobarbitone (PB; 311), lamotrigine (LTG; 55), clonazepam (CLZ; 51), phenytoin (PHT; 206), clobazam (CLB; 160), carbamazepine (CBZ; 611), valproate (VPA; 353), topiramate (TPM; 22), levetiracetam (LVT; 49), and oxcarbazepine (OXC; 76). There were 252 pregnancies without any exposure to AEDs in the first trimester, 94 of them started on AEDs later in pregnancy after the first trimester.
There was significant association between seizure burden and use of AEDs during the first trimester. Seizures occurred during the first trimester for 37 women (14.7%), who were not on any AEDs, 252 women who were on monotherapy (24.7%), and 207 who were on polytherapy (49.6%). The proportion of women who had generalized seizures among those who were not taking any AEDs (n = 17, 6.7%), was significantly (p = 0.001) lower than that of women who were on monotherapy (n = 83, 8.1%) or polytherapy (n = 59, 14.2%).
LRE group had significantly (p < 0.001) fewer WWE on VPA monotherapy (32/517; 6.2%) when compared to the GE group (236/504; 46.8%). None of the pregnancies had exposures to any teratogenic drugs, alcohol, tobacco, or radiation. Most WWE were taking folic acid during pregnancy. There were 146 women (8.6%) for whom the folic acid use could not be ascertained clearly; 138 women (8.2%) were not using folic acid during the first trimester of pregnancy. The dosage of folic acid was suboptimal (<5 mg/day) for 318 women (18.8%) and optimal for 1,542 women (91.4%).
Malformation outcome
There were 120 cases of MCMs in addition to 3 with chromosomal defects (Down syndrome) and two were genetic (tuberous sclerosis) disorders in this cohort. The MCMs pertained to the nervous system for 20 cases, cardiac for 62, gastrointestinal system including abdominal wall for 4, genitourinary system for 23, and skeletal for 22 cases. The malformations of the nervous system were neural tube defects 11 (meningo myelocoele, Chiari malformation with hydrocephalus, spina bifida), microcephaly 3, hydrocephalus requiring medical termination of pregnancy 2, congenital squint 2, and dolichocephaly with hydrocephalus and agenesis of corpus callosum one each. The malformations of heart and great vessels were atrial septal defects 39, ventricular septal defects 8, patent ductus arteriosus 8, tetralogy of Fallot 4, and coarctation of aorta and pulmonary stenosis one each. The urinary malformations were pelvic ureteric obstruction leading to hydronephrosis 8, symptomatic hydronephrosis 5, multiple cysts in kidney 3, posterior urethral valve 2, hypospadias 2, and undescended testis, agenesis of kidney, and phimosis requiring surgery one each. The skeletal defects noted were talipes equinovarus deformity 7, cleft palate or lip 7, polydactyly 4, valgus deformity 2, and phocomelia, mandibular hypoplasia, multiple skeletal malformations demanding termination one each. The malformations of gastrointestinal system and body spaces were inguinal hernia 2, and epigastric hernia, and eventration of diaphragm one each. The maternal ages of those who had MCMs (25.66 AE 3.98 years) and those who did not have MCMs (26.28 AE 4.54 years) were comparable (p = 0.145). The MCM rate for children with complete evaluation including 1-year follow-up (n = 1,099) was 6.73% (95% CI 5.36-8.33). The MCM rate according to different denominators are given in Table 2 . There was no significant difference in the MCM rates between women who had enrolled in the preconception stage and those who had enrolled after conception. Maternal socioeconomic status, epilepsy syndrome, history of malformation in maternal or paternal first-degree relatives, and seizure burden during pregnancy did not have any significant association with MCM rate (Table 3) .
AED exposure and relative risk of MCM
MCMs were observed in 14 cases among the no AED exposure group (n = 252), 65 cases of the monotherapy group (n = 1,021), and 41 cases of the polytherapy group (n = 415). The MCM rate for the polytherapy group (9.9%) was significantly higher than that for the monotherapy group (6.4%, p = 0.021) and no AED exposure group (5.6%, p = 0.049). The number of children with MCMs (MCM rate) for different AED exposures as mono or polytherapy was as follows: PB 23 (7.4), LTG 1 (1.8), CLZ 3 (5.9), PHT 12 (5.8), CLB 15 (9.4), CBZ 44 (7.2), VPA 36 (10.2), TPM 6 (27.3), LVT 2 (4.1), and OXC 6 (7.9). The external control group had lower MCM rate than the internal control group; however, the difference was not statistically significant. The MCM rates for monotherapies are given in Table 4 . The MCM rate for the CLB monotherapy (22.2%, 95% CI 6.32-54.74) and VPA monotherapy groups (8.96%, 95% CI 6.09-12.98) were high, whereas the LTG monotherapy group had the lowest MCM rate (2.63%, 95% CI 0.47-13.49). The VPA monotherapy group had significantly higher RR with reference to the external control group (Table 4) . Although the malformation rate (9.7%) for the subgroup of WWE with GE on VPA monotherapy (23/236) was higher (3.1%) than that of WWE with LRE on VPA (1/32), the difference was not statistically significant (p = 0.329). The MCM rate for CLB as monotherapy was 2 of 9 (22.2%), polytherapy with valproate 2 of 10 (20%), and polytherapy without valproate 11 of 141 (7.8%). The CLB monotherapy group had significantly higher RR of MCM when referenced to external control group and to internal control group, although the sample size for the latter was small. There were no malformations among the six cases with TPM monotherapy. However, TPM polytherapy recorded MCM in 2 of the 3 cases and involving VPA and 4 of the 13 cases excluding VPA.
AED dosage and MCM risk MCM rate had statistically significant association with higher doses of VPA. (Table 5 ). With regard to VPA, there was a significant increase in the MCM rate with even an increment of 200 mg/day (see Fig. 1 , bar chart with exponential trend line showing increasing MCM rate (y-axis) with incremental dose (mg/day) of valproate monotherapy [x-axis]). The dose dependency of the MCM rate for LVT could not be clearly assessed; there were no exposures to low dose. There was a trend toward a higher rate of MCM with higher dose of PB. There was an association between MCM rate and cumulative dose (PDD/DDD ratio) in the case of polytherapy. Cumulative dosage (PDD/DDD ratio ≤ 1) had fewer MCMs (6.1%), whereas dose ranges with PDD/DDD ratio 1.01-2 had 11.5% MCM and highest dose range (PDD/DDD ratio 2.01-3) had 12.3% MCM. With the lowest PDD/DDD ratio as reference, the relative risk of MCM for intermediate dose was 1.87 (95% CI 1.25-2.78) and highest dose was 2.01 (95% CI 1.01-4.01).
Discussion
This set of data on the pregnancy outcome and malformation risk to offspring is significant from several standpoints. This is the first large prospective dataset of pregnancy outcome and MCM risk for WWE of non-Caucasian origin and living in a low-income country. The data come from a pregnancy registry with rigorous criteria for selection, follow-up protocol, and MCM ascertainment with minimal loss to follow-up. Nearly one-fourth of the women were enrolled in this registry in the prepregnancy stage and were followed through pregnancy and delivery until the children were older than 1 year of age. The socioeconomic background, maternal and paternal education, occupation, and family income as well as their family history for MCM were available for analysis. The registry also had an external control group consisting of women without epilepsy or AED exposure enrolled in the first trimester of pregnancy and followed similar to the cases with their babies submitted to the same screening methods for MCMs.
The MCM rates (Table 2) for the unexposed groups (external control group 3.45%; internal control group 5.56%) and the exposed groups (mono and polytherapy 7.38%) are relatively higher than that reported from other pregnancy registries. To a certain extent this could be due to the rigorous methods of malformation screening that we employed such as mandatory echocardiography and ultrasonography for all children at 3 months of age.
Our data indicate that the relative risk of MCMs for those who were unexposed to AEDs in the first trimester was not significantly different from that of external control group or those who were exposed to LTG monotherapy (Table 4) . The MCM rate for the external control group was comparable to that reported from Australia 2 and Quebec, 10 but higher than that reported from the United States (1.1%). 3 In this analysis we had estimated the MCM rates according to different levels of ascertainment including and excluding fetal loss. However, there was no substantial difference in the rates between these stratifications ( Table 2) . The limitations of rates as quoted from different registries are an important issue. 11 Our MCM rate for the monotherapy group is comparable to that published from registries in United Kingdom and Ireland, 1 North America, 3 Australia, 2 and Europe and other continents, 12 although the subjects in our registry live in a low middle income country in Asia (South India) and differ in ethnic background. It appears that the ethnic background or geographic location of the population had little influence on the risk of MCMs. This is the first study that had also looked for any possible association between the socioeconomic status and MCM risk for WWE. We did not find any association between MCM risk and the socioeconomic status and risk of MCM. Maternal characteristics such as age, type of epilepsy or level of seizure control during pregnancy did not influence the MCM risk. Preconception registration or folic acid administration in first trimester did not reduce the risk for MCMs.
The relative risk of MCMs with monotherapy was significantly high for VPA when compared to the external control group (Table 4 , Fig. 1 ). This observation is in agreement with data from other pregnancy registries also. MCM risk increased significantly as the dose was increased for the VPA monotherapy. This dose dependency was maximally evident for VPA, which showed an increased risk with every increment in dosage (Fig. 1) . The dose dependency of MCM risk was evident when the PDD/DDD ratio was examined for monotherapy and polytherapy.
The RR of MCM with CLB monotherapy exposure was significantly high against the external control group and the internal control group, but the latter is based on a small sample of nine exposures. This is an important signal that needs further confirmation with a larger sample. The CLB polytherapy group also carried a high malformation risk (Table 4) . CLB is a relatively new drug in the treatment of epilepsy in India. However, it has found an important position as adjuvant AED in the pharmacotherapy of generalized epilepsy as well as localization-related epilepsy. So far there are few published data on the pregnancy outcome and MCM risk of CLB. Autoradiographic studies in rats have shown that CLB distribution in the fetuses is comparable to that in the maternal distribution. 13 With regard to TPM, we had only exposure as polytherapy, which again showed a high malformation rate (27.3%). This observation is in line with that of earlier publications. 2, 14 The higher MCM risk associated with a higher dose of LVT needs to be viewed with caution as there was no case in the lower dose group. Our study has confirmed the excess risk of MCMs associated with antenatal exposure to AEDs, particularly, VPA and polytherapy. A dose-dependent escalation in risk of MCM was observed with VPA. Maternal epilepsy characteristics or use of folic acid during the first trimester of pregnancy did not modify the MCM risk. MCM rate in this study from India with low middle income, socioeconomic background and Asian ethnicity is comparable to that reported from elsewhere. It is important to note that antenatal exposure to some of the AEDs is associated with increased risk of impaired cognitive and language development in children of WWE. 15 There are about 1.25 million WWE of reproductive age in India. The AEDs and epilepsy care offered to WWE during pregnancy need to be further customized to reduce the risk of MCMs in their babies. Clinicians need to be aware of relative safety and hazards of different AEDs, particularly VPA, and the need to avoid higher doses during pregnancy.
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